Cambrex Corporation (CBM)
(Delayed Data from NYSE)
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bet on 4 High-Flying Stocks With Increasing Cash Flows
by Zacks Equity Research
Cash indicates a company's true financial health. It holds the key to its existence, development and success.
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Explosive Returns with the Filtered Zacks Rank 5 Strategy
by Kevin Matras
Kevin Matras goes over the Filtered Zacks Rank 5 strategy. Learn how it can help you pick the best of the Zacks #1 Rank stocks. Highlighted stocks include BGFV, CBM and PLCE.
Zacks.com featured highlights: Aegean Marine Petroleum Network, Cambrex, Gibraltar Industries, State National and Stamps.com
by Zacks Equity Research
Zacks.com featured highlights: Aegean Marine Petroleum Network, Cambrex, Gibraltar Industries, State National and Stamps.com
Alnylam Reports Positive Data on Fitusiran, Givosiran
by Zacks Equity Research
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
by Zacks Equity Research
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.
Merck KGaA (MKGAF) Expands Distribution Deal with Roche
by Zacks Equity Research
Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.
5 Stocks with Solid Net Profit Margin to Bet On
by Zacks Equity Research
Net profit, also referred to as the bottom line, is one of the key tools that gauges the financial health of an enterprise.
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).
Ultragenyx (RARE) Reports Positive Phase II Study on UX007
by Zacks Equity Research
Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
by Zacks Equity Research
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
by Zacks Equity Research
Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.
Amicus Provides Regulatory Update on Fabry Disease Drug
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported adjusted earnings of $2.04 per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016), beating the Zacks Consensus Estimate of $1.98.
Zacks.com featured highlights: Alliance Resource Partners, EnerSys, Cambrex and Children's Place
by Zacks Equity Research
Zacks.com featured highlights: Alliance Resource Partners, EnerSys, Cambrex and Children's Place
Zacks.com featured highlights: Edgewell Personal Care, Cambrex, Humana, Research Frontiers and Galena Biopharma
by Zacks Equity Research
Zacks.com featured highlights: Edgewell Personal Care, Cambrex, Humana, Research Frontiers and Galena Biopharma
7 Stocks Near 52-Week Highs to Buy Right Away
by Zacks Equity Research
Though touted as one of the riskier investing techniques, a sizable number of investors are picking undervalued stocks near 52-week high with the conviction that they can scale higher.
Zacks.com featured highlights: Stamps.com, Cambrex, Gibraltar Industries and FutureFuel
by Zacks Equity Research
Zacks.com featured highlights: Stamps.com, Cambrex, Gibraltar Industries and FutureFuel
Zacks.com featured highlights: Cambrex, Gibraltar Industries, Sabre, State National and Stamps.com
by Zacks Equity Research
Zacks.com featured highlights: Cambrex, Gibraltar Industries, Sabre, State National and Stamps.com
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
by Zacks Equity Research
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on